Efficacy of Intradiscal Injection of BM-MSC in Subjects With Chronic Low Back Pain (LBP) Due to Lumbar Degenerative Disc Disease (DDD) Unresponsive (RESPINE)

A Phase 2/3 Prospective, Multicentre Randomized, Double-blind Trial, Comparing Intra-discal Allogeneic Adult BM-MSC Therapy and Sham-treated Controls in Subjects With Chronic LBP Due to Lumbar DDD Unresponsive to Conventional Therapy

This will be a multicenter, prospective, double blind, randomized phase 2/3 trial comparing culture-expanded allogeneic adult BM-MSCs with sham-treated controls.

This trial will evaluate the efficacy of intradiscal injection of BM-MSCs in chronic low back pain due to lumbar degenerative disc disease (DDD) unresponsive to conventional therapy .

Visual analog scale (VAS) and functional status (by Oswestry Disability Index - ODI) will be evaluated 12 months after treatment, defining responders in case of improvement of VAS for pain of at least 20% and 20 mm between baseline and month 12, or improvement of ODI of 20% between baseline and month 12.

Study Overview

• Status: Active, not recruiting
• Conditions: Recurrent Low Back Pain; Degenerative Disc Disease (DDD)
• Intervention / Treatment: Drug: Allogenic BM-MSCs Injection; Other: Sham Procedure

Detailed Description

Degenerative disc disease (DDD) presents a large, unmet medical need. One of the most important public health problems, it affects 70 million Europeans, accounts for 42% of patients with chronic low back pain and costs over $100 billion each year in the European Union. DDD results in a disabling loss of mechanical function. Today, no efficient therapy is available. The disease results from degeneration of cartilage discs with loss of the collagen matrix and nucleus pulposus chondrocyte. Chronic cases often receive surgery, which may lead to biomechanical problems and accelerated degeneration of adjacent segments. Our consortium partners have developed and studied stem cell-based, regenerative therapies with encouraging results in phase 1 and 2 trials. Patients exhibited rapid and progressive improvement of functional and pain indexes by 50% within 6 months and by 65% to 78% after 1 year with no side effects. In addition, MRI T2 relaxation measurements demonstrated a significant improvement of cartilage signal. To develop the world's first effective treatment of DDD, RESPINE aims to assess, via a randomized, controlled, phase 3 clinical trial including 112 patients with DDD, the efficacy of an allogenic intervertebral mesenchymal stem cell (MSC)-based therapy. This innovative therapy aims to rapidly (within 3 months) and durably (at least 24 months) reduce pain and disability. In addition, the consortium aims to provide new knowledge on immune response & safety associated with allogeneic BM-MSC intradiscal injection.

• Study Type: Interventional
• Enrollment (Actual): 113
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• France
  • Montpellier, France, 34295
    • UH Montpellier
  • Nantes, France
    • CHU de Nantes
  • Paris, France
    • Aphp Cochin
  • Paris, France, 75012
    • CHU Saint Antoine
• Germany
  • Halle, Germany, 06112
    • BG Klinikum Bergmannstrost
• Italy
  • Roma, Italy, 00128
    • Campus Bio-Medico University of Rome
• Spain
  • Barcelona, Spain, 08022
    • Institut de Teràpia Regenerativa Tissular
  • Pamplona, Spain, 31008
    • Clinica Universidad de Navarra
  • Valladolid, Spain, 47002
    • Hospital Sagrado Corazón Valladolid

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age between 18 and 60 years.
• Symptomatic chronic low back pain unresponsive to conservative therapy (including physical therapy performed during at least 1 month before inclusion and pain medication with level 2 analgesics in failure or intolerant to level during at least 1 month) for at least 3 months.
• DDD assessed by (Pfirrmann's score modified Griffith et al) grade 4 to 7 at one level. If second level, it should be adjacent (Pfirrmann's score 1-4 maximum)
• Low back Pain baseline > 40 mm on VAS (0-100).
• NSAID washout of at least 2 days before screening
• Painkillers washout of at least 24 hours before screening

Exclusion Criteria:

• Congenital or acquired diseases leading to spine deformations that may upset cell application (hyperlordosis, scoliosis, isthmus lesion, sacralization and hemisacralization).
• Symptomatic posterior lumbo-articular osteoarthritis or predominant facet syndrome on Xray or MRI (osteophyte and facet hypertrophy).
• Prior to the screening visit, has received:
• Oral corticosteroid therapy within the previous 3 months, OR
• Intramuscular, intravenous or epidural corticosteroid therapy within the previous 3 months
• Spinal segmental instability (defined by lumbar dynamic X-Ray in extension/flexion with antero-post translation > 3 mm and/or angular mobility > 15°).
• Spinal canal stenosis (Schizas score > B).
• History of spinal infection.
• Lumbar disc herniation with non truncated sciatica or cruralgia, as well as lumbar cysts and radiculopathy
• Previous discal puncture or previous spine surgery.
• DDD on 3 levels, or DDD on 2 levels but not adjacent, or DDD with modic 2 or 3 phases
• Patients not eligible to the intravertebral disc surgery
• Patients who have the risk to undergo a surgery in the next 6 months
• Obesity with body mass index (BMI in Kg/size in m2) greater than 35 (obesity grade II).
• Participation in another clinical trial or treatment with another investigational product within 30 days prior to inclusion in the study.
• Abnormal blood tests: hepatic (alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >1.5 × upper limit of normal (ULN)), renal, pancreatic or biliary disease, blood coagulation disorders, anemia or platelet count of <100 × 109/
• Significant medical problems, such as uncontrolled hypertension, symptomatic heart failure; or any other clinically relevant condition or current medication that in the opinion of the investigator contra-indicates the use of any of the study or rescue medications.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Allogenic BM-MSCs Injection; Injection of a dose of 20.106 allogenic BM-MSCs via imaging control into the disk affected by DDD where they are expected to exert their therapeutic effects.	Drug: Allogenic BM-MSCs Injection; Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution
Sham Comparator: Sham Procedure; anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment	Other: Sham Procedure; sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.; Other Names: Injection of 2 mL of 1% xylocaine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline Pain Clinical response at 12 months	The clinical response is defined as the Pain relief measure with Visual Analogue Scale (VAS) of at least 20 mm decrease on VAS scale between baseline and month 12.	baseline to month 12
Change from Baseline Oswestry Disability Index (ODI) measure at 12 months	at least 20% improvement of functional index ODI at month 12 compared to baseline.	baseline to month 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measure disability and quality of life evolution of the patient	Assessed by Short Form-36 Health Survey (SF-36) : The eight sections are vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning and mental health A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.	Baseline, 3,6,12 and 24 months
Disability and quality of life evolution	global assessment by the patient and the physician. Overall pain intensity in the lumbar spine (1 = none, 2 = mild, 3 = moderate, 4 = severe, 5 = extreme); patient's global assessment of disease activity (1 = very good, 2 = good, 3 = fair, 4 = poor, 5 = very poor); physician's global assessment of disease activity (1 = very good, 2 = good, 3 = fair, 4 = poor, 5 = very poor) will be performed at 0, 3, 6, 12 and 24 months.	baseline, 3,6,12 and 24 months
Pain killers	assessement of consumption of painkillers medication. Rescue medication use will be recorded throughout the study duration by a diary file.	baseline, 1, 3,6,12 and 24 months
Measure of the Chronic low back pain	assessement of pain by the Visual Analogue pain Scale (VAS) during 24 months. Min value 0 - max value 100 , where 0 represents no pain and 100 represents the worst pain imaginable.	baseline, 1, 3,6,12 and 24 months
Employment and work status	Assessement of employment and work status. For this, patients will be assign to one of 4 categories designated as "employable" which included those who were unemployed due to pain, employed but on sick leave, laid off, or working. The other categories include retired, disabled, and elderly at least 60 years of age, eligible for social security.	baseline, 1, 3,6,12 and 24 months
Structural assessment	Evolution of affected disc(s) by quantitative Magnetic Resonance Imaging (MRI) density measurements in T2 and T1spin/echo and T1rho weighted images performed at 0, 6 12 and 24 months used as an indication of disc fluid and glycosaminoglycan (GAG) content. The "quality" of the patient's lumbar disc will be monitored non invasively using T2-weighted MRI sagittal images (Orozco et al., 2011) and, in T1spin/echo MRI. Lumbar disc grading will be performed in the sagittal T2 weighted images by two physicians independently who were experienced in MRI of the spine. They will review each intervertebral disc from L1-2 to L5-S1 by the modified Pfirrmann criteria. The modified Pfirrmann grading system assesses degenerated intervertebral discs by MRI for the asymmetry in disc structure, distinction of the nucleus and the annulus, signal intensity of intervertebral discs and height of intervertebral discs and assigns grade 1 to 8 for disc degeneration (Table by Griffin et al. Spine 2007).	baseline, 1, 3,6,12 and 24 months
Evaluation of cost	We will compare the medical and non-medical costs between the two groups of patient. Costs will be identified for a one-year time horizon. For this purpose, resource use in each arm will be collected in physical units in the electronic Case Report Form (eCRF) at each clinical centre as follows: Acute care medical hospitalisations related to DDD; Acute care surgical hospitalisations related to DDD; Rehabilitation hospitalisations related to DDD; Analgesics; Work disruption Resource use will be valued using production costs specific to each country or to the country having included the highest number of patients, depending on the number of patients actually included in each clinical centre.	24 months
Immune response / Analytical control	The assessment of the biological effect of allogeneic MSC on recipient immune response will be studied by multiparametric flow-cytometry as well as monitoring of anti HLA-I (human leukocyte antigen I) antibodies response.	baseline, 1, and 6 months
reporting of Serious Adverse Events (SAE)	Define the safety outcomes of the clinical trial with the record of SAE	baseline, 1, 3,6,12 and 24 months

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Collaborators: National University of Ireland, Galway, Ireland; Rennes University Hospital; Nantes University Hospital; Campus Bio-Medico University; Université Montpellier; University of Navarra; APHP; University of Valladolid; Centre National de la Recherche Scientifique, France; Citospin; European Clinical Research Infrastructure Network; Institut de Terapia Regenerativa Tissular; Interdisziplinäres Zentrum Klinische Studien (IZKS); Département de l'information médicale, CHU de Montpellier; Univercell-Biosolutions S.A.S; BG Klinikum Bergmannstrost, Halle, Germany
• Investigators: Principal Investigator: Christian CJ JORGENSEN, PhD, Montpellier University Hospital

Publications and helpful links

Helpful Links

• RESPINE trial website

Study record dates

Study Major Dates

• Study Start (Actual): February 18, 2019
• Primary Completion (Actual): May 30, 2022
• Study Completion (Estimated): March 8, 2026

Study Registration Dates

• First Submitted: June 19, 2018
• First Submitted That Met QC Criteria: November 8, 2018
• First Posted (Actual): November 9, 2018

Study Record Updates

• Last Update Posted (Actual): August 14, 2023
• Last Update Submitted That Met QC Criteria: August 11, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: Low back pain; BM-MSCs; Lumbar degenerative disc disease (DDD)
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Musculoskeletal Diseases; Spinal Diseases; Bone Diseases; Back Pain; Low Back Pain; Intervertebral Disc Degeneration; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Membrane Transport Modulators; Anesthetics, Local; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Lidocaine
• Other Study ID Numbers: UF 9766

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No